I agree Darwinian...this seems to be a fairly dire

Quote:

---

BI 655066 is administered as a subcutaneous injection and was generally well-tolerated in the 12-week treatment portion of the Phase 2 study. Serious adverse events were reported for patients in the BI 655066 18mg treatment group (7.0%) and ustekinumab group (2.5%), while there were no serious adverse events in the 90 mg and 180 mg treatment groups. One patient discontinued treatment in the BI 655066 18mg dose group. The most common adverse events across the BI 655066 treatment groups were common cold and headache, at 7.3 – 11.6% across the dose groups and 2.4 – 7.0%, respectively. The most common adverse events in the ustekinumab group were common cold, injection site pain and redness, sore throat and myalgia; each of which occurred in 5.0% of patients.

BI 655066 is in Phase 2 development for Crohn’s disease and asthma, and is about to enter Phase 2 development for psoriatic arthritis. In addition, Phase 2 data for Crohn’s disease will be presented at an upcoming medical meeting.

---